Developer docs
API playgroundTry for free, no card

Search company profiles

InteRNA Technologies

Full company profile

uuid0002g4v

Namestring
InteRNA Technologies
Legal namestring
InteRNA Technologies
Company typeenum
Private
Founded yearint
2006
Descriptiontext

InteRNA Technologies is a privately held drug discovery and development company founded in 2006, operating with a headcount of 11–50 employees. Its core activity is the development of therapeutics, with the leadership and capital structure indicating a focus on microRNA-based or related nucleotide therapeutics, consistent with the investor base of specialist life sciences VCs (Aglaia BioMedical Ventures, Inkef, Aurora Science, OostNL, Alumni Ventures) and regional Dutch public capital (Innovation & Investment Fund Gelderland).

The company has progressed through multiple private financing rounds between 2010 and 2021, with the largest disclosed raise of approximately $22.4M completed in February 2021 alongside a follow-on tranche in March 2021, bringing cumulative disclosed funding to roughly $37.9M. Governance is led by CEO Roel Schaapveld, with Hans GCP Schikan serving as Chairman of the supervisory board and two Chief Development Officers (Grégoire Prévost and Michel Janicot) supporting the R&D organization. The structure is consistent with a clinical-stage or late-preclinical European biotech preparing for pipeline advancement.

The firm's go-to-market model in its current stage is capital-driven rather than revenue-driven: there are no disclosed licensing deals, partnerships, or product revenues in the data, and customer concentration in the conventional sense is not applicable at this development stage. Public-facing technical detail on the proprietary drug discovery platform, pipeline assets, or target indications is limited in the available material, which constrains deeper technical assessment.

Short descriptiontext

InteRNA Technologies is a privately held drug discovery and development company founded in 2006, with 11–50 employees, developing therapeutics and backed by specialist life sciences venture investors across multiple financing rounds totaling approximately $37.9M.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
online gambling platform, casino game aggregator, sports betting services, mobile gaming apps, slot machine games
Industry1 code
PRIMARYMPAEAKAA
iGaming Platform Providers (Turnkey/Casino & Sportsbook Platforms)
Media, Entertainment & Sports/Gambling, Betting & Casinos/Gaming Technology, Platforms & Data (iGaming Platforms, Odds, Risk, KYC)
NAICS code2 codes
  • Gambling Industries7132
  • Other Gambling Industries713290
SIC code1 code
  • Services-Miscellaneous Amusement & Recreation7990
Product category
Online Gambling and Gaming
Social media profiles1 record
Revenue model1 record
1Gaming Transaction Fees (Take Rate)
TypeTransaction Fee
Description

Platform generates revenue through transaction fees on player deposits and withdrawals. All deposit methods listed as 0% fee to players (bank transfer, SmartLink, Codepay, card recharge, MoMo, giftcode), with platform revenue derived from game margins and house edge on casino games, slot machines (nổ hũ), sports betting odds, and lottery products.

interna-technologies.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Marketing or Sales, Operations, Technology or R&D, Personnel, Infrastructure
Pricing details1 tier
1New Member Welcome Bonus
ModelOtherBilling cadencePay-as-you-go
Notes

New members receive 50,000 VND upon account registration. First deposit matched at 100% bonus.

interna-technologies.com
GTM typeB2C
B2C
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

The company operates an online gambling aggregation portal serving the Vietnamese market. Its core offering is the HD88 portal, which aggregates and promotes multiple real-money gambling sub-brands including Hdbet, Ho88, Co88, So79, Tipclub, Nohu Win, and Okvip Top, alongside the Sunwin gaming platform. The portfolio includes slot machines (Nổ Hũ), fish shooting (Bắn Cá), live casino, dice games (Tài Xỉu, Xóc Đĩa), card games, sports betting, and online lottery, accessible via web and dedicated Android/iOS mobile applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 2-5 minute withdrawal processing vs 30-60 minutes for competitors
+4 more records
Product overview1 text field

InteRNA Technologies operates a multi-platform online gaming and gambling aggregation portal serving the Vietnamese market. The core offering centers on HD88 as the primary brand, which aggregates and promotes multiple gambling sub-platforms including Hdbet, Sunwin, Ho88, Co88, So79, Tipclub, Nohu Win, and Okvip Top. The platform offers a comprehensive portfolio of gambling categories including slot machines (Nổ Hũ) with jackpot prizes up to 50 billion VND, fish shooting games (Bắn Cá), live casino (Casino Trực Tuyến), online dice games (Tài Xỉu, Xóc Đĩa), card games (Game Bài) like Tiến Lên and Phỏm, sports betting through K Sports, S Sports, IM Sports and B Sports, and online lottery (Lô Đề). Sunwin provides dedicated mobile applications for Android and iOS, along with a multi-method payment system supporting bank transfers, e-wallets, and mobile cards. The various sub-brands operate as distinct gambling platforms under promotional aggregation, each with their own member benefits and promotional structures.

Product and service9 records
1HD88
CategoryOnline gambling aggregator portal
2Hdbet (HDBET)
CategoryOnline gambling sub-platform
3Ho88
CategoryOnline gambling sub-platform
4Co88
CategoryOnline gambling sub-platform
5So79
CategoryOnline gambling sub-platform
6Tipclub
CategoryOnline gambling sub-platform
7Nohu Win (Nohuwin)
CategoryOnline gambling sub-platform
8Okvip Top
CategoryOnline gambling sub-platform
9Sunwin
CategoryOnline gaming and gambling platform
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO providing preclinical drug-discovery, safety assessment, and manufacturing services to pharma and biotech. Directly comparable as a drug-discovery services platform but operating at vastly greater scale across the full development pipeline.

TypeDirect peer
Description

German-headquartered drug-discovery and development services company offering integrated small-molecule and biologics discovery platforms to pharma partners. Closely comparable business model, target customer set, and European base.

TypeBroad incumbent
Description

China-based CRO/CDMO offering end-to-end drug-discovery, preclinical, and manufacturing services globally. Comparable discovery-services offering, though operating at significantly larger scale and with broader geographic reach.

TypeDirect peer
Description

China/UK-based CRO providing drug-discovery, preclinical, and clinical development services to biotech and pharma clients. Comparable fee-for-service drug-discovery model with similar customer profile.

TypeDirect peer
Description

UK-based drug-discovery CRO specialising in medicinal chemistry, in vitro biology, and DMPK for pharma partners. Closely comparable size, scope, and customer type as a mid-sized European drug-discovery services firm.

TypeBroad incumbent
Description

Global bioanalytical and contract-testing group with significant drug-discovery and pharma-services operations. Comparable in services offering but operates across many adjacent verticals (food, environmental, clinical) at much larger scale.

TypeDirect peer
Description

Global CRO providing preclinical drug-discovery and translational oncology services to pharma and biotech clients. Comparable mid-sized CRO with overlapping discovery-services business.

TypeOthers
Description

German supplier of bioprocessing and lab technologies used in drug discovery and biomanufacturing. Adjacent rather than directly competitive, but a likely vendor/customer relationship for any biotech discovery services platform.

TypeOthers
Description

Swiss CDMO providing development and manufacturing services for biologics and small molecules. Adjacent rather than directly competitive, but a potential upstream/downstream partner for a discovery-stage biotech.

TypeEmerging player
Description

Developer of life-science reagents, assays, and exosome-based platforms used in drug discovery and translational research. Partial overlap with the discovery-tools ecosystem and a comparable sub-scale peer in the broader biotech-tools category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InteRNA Technologies

Online Gambling and Gaminginterna-technologies.com

InteRNA Technologies is a privately held drug discovery and development company founded in 2006, with 11–50 employees, developing therapeutics and backed by specialist life sciences venture investors across multiple financing rounds totaling approximately $37.9M.

What InteRNA Technologies does

InteRNA Technologies is a privately held drug discovery and development company founded in 2006, operating with a headcount of 11–50 employees. Its core activity is the development of therapeutics, with the leadership and capital structure indicating a focus on microRNA-based or related nucleotide therapeutics, consistent with the investor base of specialist life sciences VCs (Aglaia BioMedical Ventures, Inkef, Aurora Science, OostNL, Alumni Ventures) and regional Dutch public capital (Innovation & Investment Fund Gelderland).

The company has progressed through multiple private financing rounds between 2010 and 2021, with the largest disclosed raise of approximately $22.4M completed in February 2021 alongside a follow-on tranche in March 2021, bringing cumulative disclosed funding to roughly $37.9M. Governance is led by CEO Roel Schaapveld, with Hans GCP Schikan serving as Chairman of the supervisory board and two Chief Development Officers (Grégoire Prévost and Michel Janicot) supporting the R&D organization. The structure is consistent with a clinical-stage or late-preclinical European biotech preparing for pipeline advancement.

The firm's go-to-market model in its current stage is capital-driven rather than revenue-driven: there are no disclosed licensing deals, partnerships, or product revenues in the data, and customer concentration in the conventional sense is not applicable at this development stage. Public-facing technical detail on the proprietary drug discovery platform, pipeline assets, or target indications is limited in the available material, which constrains deeper technical assessment.

InteRNA Technologies firmographics

Firmographics
Name
InteRNA Technologies
Legal name
InteRNA Technologies
Website
https://interna-technologies.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
InteRNA Technologies is a privately held drug discovery and development company founded in 2006, with 11–50 employees, developing therapeutics and backed by specialist life sciences venture investors across multiple financing rounds totaling approximately $37.9M.
Ownership category
akta.pro rank

InteRNA Technologies industry classification

Industry
Product category
Online Gambling and Gaming
NAICS
Gambling Industries (7132), Other Gambling Industries (713290)
SIC
Services-Miscellaneous Amusement & Recreation (7990)
akta.pro industry
PRIMARYMPAEAKAA
iGaming Platform Providers (Turnkey/Casino & Sportsbook Platforms)
Media, Entertainment & Sports/Gambling, Betting & Casinos/Gaming Technology, Platforms & Data (iGaming Platforms, Odds, Risk, KYC)

Keywords

  • Online gambling platform
  • Casino game aggregator
  • Sports betting services
  • Mobile gaming apps
  • Slot machine games

Where InteRNA Technologies is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Markets served

InteRNA Technologies business model

Business model
GTM type
B2C
Offering type
Digital Commerce or Content
Cost components
Marketing or Sales, Operations, Technology or R&D, Personnel, Infrastructure

Revenue model

  1. Gaming Transaction Fees (Take Rate): Platform generates revenue through transaction fees on player deposits and withdrawals. All deposit methods listed as 0% fee to players (bank transfer, SmartLink, Codepay, card recharge, MoMo, giftcode), with platform revenue derived from game margins and house edge on casino games, slot machines (nổ hũ), sports betting odds, and lottery products.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNew Member Welcome Bonus

Distribution channels3 records

Marketing channels3 records

InteRNA Technologies product offering

Product offering

Core offering

The company operates an online gambling aggregation portal serving the Vietnamese market. Its core offering is the HD88 portal, which aggregates and promotes multiple real-money gambling sub-brands including Hdbet, Ho88, Co88, So79, Tipclub, Nohu Win, and Okvip Top, alongside the Sunwin gaming platform. The portfolio includes slot machines (Nổ Hũ), fish shooting (Bắn Cá), live casino, dice games (Tài Xỉu, Xóc Đĩa), card games, sports betting, and online lottery, accessible via web and dedicated Android/iOS mobile applications.

Product overview

InteRNA Technologies operates a multi-platform online gaming and gambling aggregation portal serving the Vietnamese market. The core offering centers on HD88 as the primary brand, which aggregates and promotes multiple gambling sub-platforms including Hdbet, Sunwin, Ho88, Co88, So79, Tipclub, Nohu Win, and Okvip Top. The platform offers a comprehensive portfolio of gambling categories including slot machines (Nổ Hũ) with jackpot prizes up to 50 billion VND, fish shooting games (Bắn Cá), live casino (Casino Trực Tuyến), online dice games (Tài Xỉu, Xóc Đĩa), card games (Game Bài) like Tiến Lên and Phỏm, sports betting through K Sports, S Sports, IM Sports and B Sports, and online lottery (Lô Đề). Sunwin provides dedicated mobile applications for Android and iOS, along with a multi-method payment system supporting bank transfers, e-wallets, and mobile cards. The various sub-brands operate as distinct gambling platforms under promotional aggregation, each with their own member benefits and promotional structures.

Differentiator

Problem solved

Functional benefit

Products and services

  • HD88
  • Hdbet (HDBET)
  • Ho88
  • Co88
  • So79
  • Tipclub
  • Nohu Win (Nohuwin)
  • Okvip Top
  • Sunwin

Quantifiable outcome

  • 2-5 minute withdrawal processing vs 30-60 minutes for competitors
  • +4 more outcomes

Companies that use InteRNA Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

InteRNA Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

InteRNA Technologies partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

InteRNA Technologies competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Global CRO providing preclinical drug-discovery, safety assessment, and manufacturing services to pharma and biotech. Directly comparable as a drug-discovery services platform but operating at vastly greater scale across the full development pipeline.
  • WuXi AppTec: China-based CRO/CDMO offering end-to-end drug-discovery, preclinical, and manufacturing services globally. Comparable discovery-services offering, though operating at significantly larger scale and with broader geographic reach.
  • Eurofins Scientific: Global bioanalytical and contract-testing group with significant drug-discovery and pharma-services operations. Comparable in services offering but operates across many adjacent verticals (food, environmental, clinical) at much larger scale.

Direct peers

  • Evotec SE: German-headquartered drug-discovery and development services company offering integrated small-molecule and biologics discovery platforms to pharma partners. Closely comparable business model, target customer set, and European base.
  • Pharmaron: China/UK-based CRO providing drug-discovery, preclinical, and clinical development services to biotech and pharma clients. Comparable fee-for-service drug-discovery model with similar customer profile.
  • Sygnature Discovery: UK-based drug-discovery CRO specialising in medicinal chemistry, in vitro biology, and DMPK for pharma partners. Closely comparable size, scope, and customer type as a mid-sized European drug-discovery services firm.
  • Crown Bioscience: Global CRO providing preclinical drug-discovery and translational oncology services to pharma and biotech clients. Comparable mid-sized CRO with overlapping discovery-services business.

Others

  • Sartorius AG: German supplier of bioprocessing and lab technologies used in drug discovery and biomanufacturing. Adjacent rather than directly competitive, but a likely vendor/customer relationship for any biotech discovery services platform.
  • Lonza Group: Swiss CDMO providing development and manufacturing services for biologics and small molecules. Adjacent rather than directly competitive, but a potential upstream/downstream partner for a discovery-stage biotech.

Emerging players

  • Bio-Techne: Developer of life-science reagents, assays, and exosome-based platforms used in drug discovery and translational research. Partial overlap with the discovery-tools ecosystem and a comparable sub-scale peer in the broader biotech-tools category.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

InteRNA Technologies social profiles

Digital presence

InteRNA Technologies compliance and trust

Trust signal

Compliance4 records

InteRNA Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InteRNA Technologies leadership team

Management profile

Number of profiles

InteRNA Technologies funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InteRNA Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InteRNA Technologies

What does InteRNA Technologies do?

The company operates an online gambling aggregation portal serving the Vietnamese market. Its core offering is the HD88 portal, which aggregates and promotes multiple real-money gambling sub-brands including Hdbet, Ho88, Co88, So79, Tipclub, Nohu Win, and Okvip Top, alongside the Sunwin gaming platform. The portfolio includes slot machines (Nổ Hũ), fish shooting (Bắn Cá), live casino, dice games (Tài Xỉu, Xóc Đĩa), card games, sports betting, and online lottery, accessible via web and dedicated Android/iOS mobile applications.

Is InteRNA Technologies a public or private company?

InteRNA Technologies is a private company. It is classified as unknown and is currently operating.

When was InteRNA Technologies founded?

InteRNA Technologies was founded in 2006. It employs 11 to 50 people.

Where is InteRNA Technologies based?

InteRNA Technologies is headquartered in New Haven, United States, in the North America region.

How does InteRNA Technologies make money?

One revenue line is on record: gaming Transaction Fees (Take Rate).

Who are InteRNA Technologies's main competitors?

Broad incumbents on record are Charles River Laboratories, WuXi AppTec and Eurofins Scientific. Direct peers are Evotec SE, Pharmaron, Sygnature Discovery and Crown Bioscience. Others are Sartorius AG and Lonza Group. Bio-Techne is listed as an emerging player.

Does InteRNA Technologies have an API?

No public API is recorded for InteRNA Technologies.

What industry is InteRNA Technologies in?

InteRNA Technologies's product category is Online Gambling and Gaming. Its primary akta.pro industry code is MPAEAKAA, iGaming Platform Providers (Turnkey/Casino & Sportsbook Platforms). Its NAICS code is 7132 and its SIC code is 7990.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceInteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory BoardInteRNA Technologies established a Clinical Advisory Board and appointed new members to its Scientific Advisory Board. The boards will guide development of its miRNA-based cancer therapies, including lead candidate INT-1B3. The appointments aim to accelerate clinical-stage development and pipeline expansion.PR NewswireGlobal $3.6 Billion microRNA Markets to 2028 to Grow by 19.8%Research and Markets has published a report estimating the global microRNA market will reach $3.6 billion by 2028, growing at a CAGR of 19.8% from 2021 to 2028, driven by expanding research into miRNA therapeutics and COVID-19 related applications. The report highlights that consumables captured the largest revenue share in 2020, while infectious disease applications generated the highest revenue due to increased adoption of miRNA isolation kits in COVID-19 research and diagnostic workflows. In February 2021, InteRNA Technologies raised $22.46 million in a Series B funding round led by AurorA Science to advance its microRNA lead candidate INT-1B3 for treating advanced solid tumors.FinSMEsInteRNA Technologies Extends Series B Financing Round Totaling €18.5MInteRNA Technologies closed an extended Series B financing round totaling €18.5M, led by AurorA Science with Waterman Ventures. The funding will enable clinical evaluation of its microRNA lead candidate INT-1B3 in advanced solid tumors and advance additional preclinical candidates. Gabriele Campi, PhD, will join the board.BioWorldInterna closes $22M series B round as it enters the clinicInterna Technologies BV completed a €18.5 million (US$22.4 million) Series B funding round in two stages. The company moved its first microRNA-based drug development program into the clinic after a COVID-19-induced delay.